Despite its efficacy, idarucizumab has limitations. It is specifically tailored for dabigatran and does not reverse other anticoagulants. Additionally, while it provides a rapid reversal of anticoagulation, it does not address the potential underlying causes of bleeding, such as trauma or coagulopathy. Therefore, comprehensive patient management and supportive care are essential for optimal outcomes.
